Rheumatoid arthritis (RA), a class of inflammatory disorder which imposes a tremendous economic burden on society. With time the chances of long-term disability and morbidity rise as well. Nadkarni A and colleagues conducted a retrospective, observational cohort study to compare healthcare costs and biologic persistence among RA patients who start treatment with subcutaneous first or second-line etanercept, abatacept or adalimumab. The RA patients who began with any of three treatments between July 29, 2011, to July 1, 2015, were included in the study. Multivariable Cox, proportional hazards regression, is used to measure biologic persistence. Total healthcare costs were estimated at baseline and follow-up. The patients treated with subcutaneous abatacept showed minimum adjusted hazards of non-persistence numerically and enhanced total healthcare costs from the baseline. The sensitivity analysis showed persistent results over another follow-up definition. The patients under abatacept treatment observed to have poorest health status still exhibit minimum rise in healthcare costs and sustained biologic persistence from baseline.